Literature DB >> 29752824

Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access.

Gershwin Blyden1, Kenneth R Bridges2, Lanetta Bronte1.   

Abstract

Entities:  

Keywords:  HbS; sickle cell disease; transfusion; vaso-occlusive crisis; voxelotor

Year:  2018        PMID： 29752824     DOI： 10.1002/ajh.25139

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

1.  Curative vs targeted therapy for SCD: does it make more sense to address the root cause than target downstream events?

Authors:  Marilyn J Telen
Journal:  Blood Adv       Date:  2020-07-28

2.  Optimal disease management and health monitoring in adults with sickle cell disease.

Authors:  Jo Howard; Swee Lay Thein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 3.  Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.

Authors:  Maurice H Dick; Arowa Abdelgadir; Vaishnavi Vijaya Kulkarni; Hamna Akram; Abanti Chatterjee; Sushil Pokhrel; Safeera Khan
Journal:  Cureus       Date:  2022-05-11

4.  Voxelotor treatment of a patient with sickle cell disease and very severe anemia.

Authors:  Arun S Shet; Laurel Mendelsohn; Julia Harper; David Ostrowski; Eric R Henry; Eveline Gwaabe; Jim Nichols; Abdu I Alayash; William A Eaton; Swee Lay Thein
Journal:  Am J Hematol       Date:  2019-01-08       Impact factor: 10.047

Review 5.  Pain in sickle cell disease: current and potential translational therapies.

Authors:  Varun Sagi; Aditya Mittal; Huy Tran; Kalpna Gupta
Journal:  Transl Res       Date:  2021-03-09       Impact factor: 10.171
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.